First-Line Tislelizumab Plus Chemotherapy for Esophageal Squamous Cell Carcinoma with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-306

20255 citationsJournal Articlehybrid Open Access

Authors

ClinicalTrials.gov NCT03783442.

Good health and well-being

Published in: Advances in Therapy

Volume 42, Issue 5, pp. 2269-2284

Field-Weighted Citation Impact: 10.05